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Abstract—In this study, we executed a genomic analysis with 
the objective of selecting a set of genes (possibly small) that would 
help in the detection and classification of samples from patients 
affected by Parkinson Disease. We performed a complete data 
analysis and during the exploratory phase, we selected a list of 
differentially expressed genes. Despite their association with the 
diseased state, we could not use them as a biomarker tool. 
Therefore, our research was extended to include a multivariate 
analysis approach resulting in the identification and selection of a 
group of 20 genes that showed a clear potential in detecting and 
correctly classify Parkinson Disease samples even in the presence 
of other neurodegenerative disorders.  
Keywords—Genes, machine learning, data mining, multivariate 
analysis, biomarker, Parkinson’s Diseases 
I. INTRODUCTION 
We will analyze the microarray expression data of patients 
affected by Parkinson’s disease (PD) with the goal of 
identifying a biomarker for this condition. The expression 
dataset used in this research is the 
Parkinson_105_from_CEL.xls file [1] containing the data from 
the GEO accession GSE6613 generated using the MAS5 
algorithm. 
 
The dataset contains a total of 22,283 measurements of gene 
expression from samples belonging to three distinct groups of 
people for a total of 105 samples: 
 
1. Parkinson’s disease group (50 patients) 
2. Healthy control group. (22) 
3. Neurodegenerative control group. (33) 
 
The disease control group (3) contains samples from 
patients with various neurodegenerative diseases: from 
Alzheimer to system atrophy. This control group might have 
characteristics that mimic symptoms of PD and will help to 
increase the specificity of the resulting biomarker.  
    
II. DATA PREPARATION 
The sample’s columns in the original dataset have been 
renamed in order to easily identify the class to which each 
sample belongs. In particular the name for each sample has 
been prefixed with HC, ND or PD where: 
 
HC: Health Control sample 
ND: Neurodegenerative sample 
PD: Parkinson Disease sample 
 
The prefix is followed by a sequence number for a unique 
identification within the same group. 
 
Example: “HC_01_log_z” represents a healthy control 
samples that has been transformed and standardized. 
 
Before any scaling and/or normalization on the data we 
removed probesets whose expression measurements are not 
reliable or represent experimental noise. As filtering method we 
used the “filtering by Present calls” with a threshold of 25%. 
Relaxing this threshold to a value of 25% is reasonable due to 
the high number of samples in the dataset as suggested in [2]:  
 
“For data sets with 3-4 samples 50% Present spares most of 
the probe sets significant at p 0.001 and those probes sets 
found most consistently. For more samples, relaxing the 
threshold to 25% fraction Present is reasonable”. 
 
After the filtering phase the number of probesets dropped 
from 23,283 to 8,100. During this process, we also eliminated  
probesets with expression amplitude below the noise level 
(<100) since they represent nothing but noise. 
 
The data was, then, analyzed and as expected it showed a 
strong right-skewness. In figure 1 we can see the effect of the 
logarithmic transformation on one of the control sample.  
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FIGURE 1. EFFECT OF LOGARITHMIC TRANSFORMATION 
 We then derived the z-score for each probeset defined as: 
 
 
 
where  and  are the mean and standard deviation of 
the ith probeset expression levels. 
 
We used the z-score for normalizing the data, but also to 
detect the presence of possible outliers. During this process we 
were able to find some anomalous values in the dataset. By 
anomalous value we mean an observation that appears to be 
inconsistent when compared with values belonging to the same 
class for the same gene. We marked as possible outlier any 
value with an absolute z score value greater than 5. 
 
An example of possible outlier can be found in the 49th 
sample for the 200028_at probeset in the Parkinson class. In 
this case the expression level is too low when compared to the 
other measurement in the same class. In fact, the average 
expression value in this class is 215.216; however the 
expression value for this particular sample is 30.72 indicating a 
possible defective probe. 
 
Since outliers might negatively influence analysis results we 
decided to investigate more closely and found a total of 643 
outliers. How to deal with outliers in microarray data is not a 
straightforward topic, so we decided to replace these values 
with the average within their respective class: this might not be 
the best solution, however, it will limit the influence of such 
anomalous values during the data processing phase, especially 
in cases of algorithms sensitive to outliers. 
As input in the next phases we prepared a dataset that: 
 
- Does not contain unreliable or noise probesets. 
- Does not contain outlier. 
- Contains normalized and standardized value.  
 
We decided on these characteristics by noticing that almost 
all algorithms have better performance with a dataset that has 
been normalized and standardized. By “better performance” we 
mean at least one of the following: 
 
- An improvement on processing time. 
- An improvement on classification. 
 
III. EXPLORATORY DATA ANALYSIS 
We performed the univariate analysis with the goal of 
building a ranking of differentially expressed genes. We point 
out that this result is a univariate result in which each gene is 
considered in isolation and excluding its (possibly important) 
interaction with all other genes in the dataset; consequently the 
list of genes resulting from this task should not be used as 
biomarker in a classification system.  
 
The problem of building a biomarker for Parkinson disease 
will be considered in the next sections. 
 
For the basic exploratory analysis we process our data using 
the “GenePattern” application from the MIT institute [3]. 
 
For each gene, the application uses a test statistic to 
calculate the difference in gene expression between classes and 
then computes a p-value to estimate the significance of the test 
statistic score. Because testing tens of thousands of genes 
simultaneously increases the possibility of mistakenly 
identifying a non-differentially expressed gene as a 
differentially expressed gene (a false positive), GenePattern 
corrects for multiple hypothesis testing by computing both false 
discovery rates (FDR) and family-wise error rates (FWER) 
adjusted using the Bonferroni/Hochberg method. Researchers 
using GenePattern generally identify differentially expressed 
genes based on FDR rather than the more conservative FWER. 
 
The first list of differentially expressed genes was obtained 
by running the dataset using the adjusted ANOVA F-test 
statistic with 1,000 permutations on all three sample classes. In 
order to compare results we ran the same test using the SNR 
(Signal to Noise Ratio) and the results were identical showing 
that, for this dataset, the adjusted ANOVA F-test and SNR 
results coincided when compared to the final ranking of genes. 
 
The test statistics are defined in GenePattern as the 
following: 
t-Test:      
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where Ab are the group averages, A,B the group 
standard deviations, and nA, nB the group sizes.   
 
SNR:       
 
where AB are the group averages and A,B the group 
standard deviations 
 
The application of this technique on a multiclass dataset 
generated a list of genes that: 
 
- Are up-regulated in PD (Parkinson Disease) when 
compared with the other classes  
- Are up-regulated in the other classes but down-regulated 
in PD. The result of this analysis does not indicate which 
class contains the up-regulated gene(s), so a further 
analysis is warrant between the healthy control and the 
neurodegenerative samples. 
 
FIGURE 2. UP REGULATED FEATURES 
From the graph we were able to identify 60 genes with an 
adjusted FDR (Bonferroni/Hochberg) less than 0.01. 
 
We conclude this section by displaying the heat map of the 
top 40 genes as in figure 3. It was our intention to display the 
heat map for all 60 genes, but it would have been impossible to 
fit in this page. 
 
FIGURE 3. HEAT MAP FOR THE TOP 40 GENES RANKED BY FDR 
 
 
In the image we can clearly distinguish areas in which the 
genes in each class are up or down regulated. The difference is 
more evident between samples in the Parkinson class when 
compared with the other two. More importantly we can clearly 
distinguish the difference in expression levels of genes between 
the Parkinson and the neuro-degenerative classes. This might 
be an important finding since the neuro-degenerative class has 
been introduced in the dataset in order to verify the prediction 
power of any biomarker for Parkison disease. 
 
IV. MULTIVARIATE MODELLING 
In this section we will try to build a subset of features (as 
small as possible) that will be used as a multivariate 
classification model that will differentiate classes represented 
in the data set. 
 
Multivariate analysis considers the simultaneous effect of 
genes instead of stopping to the influence of single genes, 
which is typical of univariate approaches [4].  
 
For this particular task we used the feature selection of 
Weka [5] ver. 3.4 called “Attribute Selection”.  
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Weka provides a rich set of multivariate algorithms and we 
considered: 
 
 Wrapper Subset Evaluator (WSE): implementation of 
forward wrapper method for feature selection for the creation 
of an optimal subset. 
 Correlation-based Feature Selection (CFS): evaluation of 
different combinations of features to identify an optimal 
subset. The feature subsets are generated using different 
search techniques. We used Best First and Greedy search 
methods with a forward direction. 
 R-Support Vector Machine (RSVM): SVM in its recursive 
version.  
TABLE 1 – GENES SETS IDENTIFIED BY EACH MODEL 
 
Algorithms # of 
features 
Selected 
Selected  
Subset 
WSE 6 200639_s_at 
202690_s_at 
203303_at 
207730_x_at 
211275_s_at 
217301_x_at 
SVM 20 202581_at    214800_x_at 
208843_s_at  220897_at 
207205_at    212994_at 
219055_at    220471_s_at 
212176_at    204031_s_at 
201186_at    219156_at 
219186_at    217142_at 
206342_x_at  33814_at 
213891_s_at  213340_s_at 
217552_x_at  211989_at 
CFS 39 200994_at    201935_s_at 
202169_s_at  202213_s_at 
202258_s_at  202347_s_at 
202690_s_at  202727_s_at 
202778_s_at  203104_at 
203116_s_at  203153_at 
203273_s_at  203303_at 
203992_s_at  204255_s_at 
207205_at    207416_s_at 
208666_s_at  209048_s_at 
209303_at    210647_x_at 
210858_x_at  211406_at 
213596_at    214800_x_at 
215158_s_at  216341_s_at 
216524_x_at  216600_x_at 
217301_x_at  217819_at 
217922_at    218236_s_at 
218680_x_at  219055_at 
220529_at    221192_x_at 
AFFX-HSAC07/X00351_M_at 
In all cases, we used 10 folds cross-validation method 
during the feature selection process, and in table 2 we report the 
parameters used in configuring the various algorithms in order 
to produce the feature subset. 
 
TABLE 2 – MODEL CONFIGURATION 
 
Algorithm Implementation Parameters  
WSE WrapperSubsetEval Rules: 
DecisionTable 
Fold: 5 
Search: 
GreedyStepwise 
 
SVM SVMAttributeEval Attribute to 
Eliminate per 
Iteration: 1 
Filter Type: No 
normalization 
Search: Ranker 
 
CFS CfsSubsetEval Search: 
GreedyStepwise 
 
 
Any parameter not expressively present in the table has been 
used with its default value. 
 
In order to validate each model we used the “Weka Flow 
Knowledge” environment that allows the creation of cross-
validation set and verify the classification model as shown in 
figure 4. 
 
FIGURE 4. WEKA KNOWLEDGE FLOW 
 
The “Cross Validation Fold Maker” performs a cross-
validation, in which feature selection is performed during 
training of each model. 
 
We noticed that each model performs better with its own 
particular classifier: so WSE performs better with NaiveBayes, 
CFS achieves high classification rates using neural networks 
LVQ while SVM performs well with SMO. 
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TABLE 3 – CLASSIFICATION RESULTS 
 
Model Classification Results 
WSE = Stratified cross-validation = Summary = 
 
Correctly Classified   (69)      65.7143 % 
Incorrectly Classified (36)      34.2857 % 
Kappa statistic                   0.4011 
Mean absolute error               0.3245 
Root mean squared error           0.4182 
Relative absolute error          77.0204 % 
Root relative squared error      91.1559 % 
Total Number of Instances       105      
 
=== Confusion Matrix === 
  a  b  c   <-- classified as 
  4  6 12 |  a = HC 
  0 17 16 |  b = ND 
  0  2 48 |  c = PD 
 
CFS = Stratified cross-validation = Summary = 
 
Correctly Classified   (59)      73.75  % 
Incorrectly Classified (21)      26.25  % 
Kappa statistic                   0.577 
Mean absolute error               0.175  
Root mean squared error           0.418 
Relative absolute error          41.403 % 
Root relative squared error      91.013 % 
Total Number of Instances       105      
 
=== Confusion Matrix === 
 
  a  b  c   <-- classified as 
  9  3  5 |  a = HC 
  1 19  5 |  b = ND 
3  4 31 |  c = PD 
 
RSVM = Stratified cross-validation = Summary = 
 
Correctly Classified   (87)      82.8571 % 
Incorrectly Classified (18)      17.1429 % 
Kappa statistic                   0.7228 
Mean absolute error               0.2667 
Root mean squared error           0.3432 
Relative absolute error          63.2941 % 
Root relative squared error      74.8253 % 
Total Number of Instances       105      
 
=== Confusion Matrix === 
 
  a  b  c   <-- classified as 
 16  0  6 |  a = HC 
  2 26  5 |  b = ND 
  1  4 45 |  c = PD 
 
 
From the results in table 3, we can see how the RSVM 
algorithm performed better than WSE and CFS even though 
WSE provided the smallest subset with only 6 genes. 
  
The higher classification rate for the SVM is due to its 
capability of correctly identify the difference between ND and 
PD, something that is missing from WSE and CFS which 
incorrectly misclassified many healthy tissues. 
 
The many algorithms had many options and tuning 
parameters and we are confident that all three classification 
models could be improved both at the feature selection and 
classification levels. 
 
V. CONCLUSIONS AND FURTHER WORK 
Multivariate models are a necessary tools in genomic 
studies that could be applied for the detection and 
identification of neurodegenerative conditions like 
Parkinson’s disease. 
 
Among the algorithms tested in this study, RSVM clearly 
came out as an effective model to adopt in biomarker 
discovery, with the important ability of successfully 
discriminate between PD and other neurodegenerative 
diseases. 
 
The identification of a small multivariate set of genes 
associated to PD is an important step forward in Genomics, 
but this research cannot stop here, and the natural next step is 
to look for the biological interpretation of this result.  
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